Pharmaceutical Executive May 2016

May 2016 | Volume 36, Issue 5
From the Editor
The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting. William Looney reports.
Columns
The industry has much to be optimistic about in 2016. But a look at the winner of our “Anti-Brand of the Year” clarifies how many outside the industry really see it.
Policymakers seek to limit prescribing while also encouraging innovative R&D.
Features
Pharm Exec’s 10th annual Brand of the Year has raced into the lead position in the treatment-shifting immuno-oncology space.
Pharm Exec speaks with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.
A “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.
Special Sponsored Section
By Pharmaceutical Executive Editors
While France remains a global force in the pharmaceutical, medical device, and vaccines fields—and continues to tout a solid manufacturing base and re-exportation culture—questions are arising over the long-term sustainability of the country’s healthcare system and its traditionally generous public health provisions.
native1_300x100
lorem ipsum